Stacey Solomon's go-to vitamin C serum is currently on sale for £15 *affiliate links*
She’s known for being mega relatable, and Stacey Solomon’s beauty routine is just as accessible for everyone – especially when it’s reduced in the sale.
The L'Oréal Paris Revitalift Vitamin C serum works to visibly brighten your skin and reduced the appearance of fine lines, pores, and uneven skin texture, to leave you with smoother, more even looking skin. Vitamin C can also react with other products such as retinols, making your skin more sensitive, so many sure you check the ingredients you’re using, and consider alternating the days between using your retinol and your vitamin C serum It can also cause an increase in photosensitivity, so you should always make sure you apply plenty of SPF after using a vitamin C-based product.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
I changed from a £230 perfume to a £15 fragrance and smell like 'sensual luxury'Straying from my usual vanilla based scents, I decided to try Thomson Carter - the brand that claims to be 'redefining the scent of luxury and success'
Read more »
Stacey Solomon says Joe Swash has 'never been sexier' covered in baby sickStacey Solomon revealed to fans that she is finding her husband Joe Swash has 'never been sexier,' despite being covered in baby sick, and that they 'should stay away from each other'
Read more »
Stacey Solomon shows off natural beauty as she poses with Rose in white bikiniStacey Solomon is loved for her down-to-earth attitude, and she was just that on Tuesday, as she shared a snap of herself in a white bikini after enjoying a pool day with her children
Read more »
Shoppers hail £4.49 serum that's 'much better than more expensive versions'A shopper said: 'One of the best serums around' Aff
Read more »
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens - Journal of Translational MedicinePurpose To evaluate a new class of blood-based biomarkers, anti-frameshift peptide antibodies, for predicting both tumor responses and adverse immune events to immune checkpoint inhibitor (ICI) therapies in advanced lung cancer patients. Experimental design Serum samples were obtained from 74 lung cancer patients prior to palliative PD-(L)1 therapies with subsequently recorded tumor responses and immune adverse events (irAEs). Pretreatment samples were assayed on microarrays of frameshift peptides (FSPs), representing ~ 375,000 variant peptides that tumor cells can be informatically predicted to produce from translated mRNA processing errors. Serum-antibodies specifically recognizing these ligands were measured. Binding activities preferentially associated with best-response and adverse-event outcomes were determined. These antibody bound FSPs were used in iterative resampling analyses to develop predictive models of tumor response and immune toxicity. Results Lung cancer serum samples were classified based on predictive models of ICI treatment outcomes. Disease progression was predicted pretreatment with ~ 98% accuracy in the full cohort of all response categories, though ~ 30% of the samples were indeterminate. This model was built with a heterogeneous sample cohort from patients that (i) would show either clear response or stable outcomes, (ii) would be administered either single or combination therapies and (iii) were diagnosed with different lung cancer subtypes. Removing the stable disease, combination therapy or SCLC groups from model building increased the proportion of samples classified while performance remained high. Informatic analyses showed that several of the FSPs in the all-response model mapped to translations of variant mRNAs from the same genes. In the predictive model for treatment toxicities, binding to irAE-associated FSPs provided 90% accuracy pretreatment, with no indeterminates. Several of the classifying FSPs displayed sequence similarity
Read more »
Effects of serum sodium and chloride levels in the outcome of critically ill pediatric patients in the post-operative period of liver transplantation - BMC NephrologyBackground Sodium and chloride disturbances have attracted increasing attention in recent years. Many pathophysiological effects are associated with hyperchloremia, including reduction in mean arterial pressure and acute renal disease. Pediatric patients undergoing liver transplantation are at risk of developing various electrolyte and biochemical abnormalities, with an impact on their postoperative outcomes. Objective To analyze the impacts of serum sodium and chloride levels on prognosis of Pediatric Liver Transplant receptors. Methods This was a retrospective analytical observational study performed in a single transplant reference center in Sao Paulo, Brazil. Included patients were pediatric patients who underwent liver transplantation between January 2015 and July 2019. Statistical regression analysis and General Estimating Equations analysis were performed to evaluate the impacts of sodium and chloride disturbances on the development of acute renal failure and mortality. Results A total of 143 patients were included in this study. The main diagnosis was Biliary Atresia (62.9%). Twenty-seven patients died (18.9%), and graft dysfunction was the main cause of death (29.6%). The only variable individually associated with 28-days mortality was PIM-3 score (HR 1.59, CI 95% 1.165–2.177, p = 0.004). Forty-one patients (28.6%) developed moderate or severe AKI. PIM-3 score (OR 3.052, 95% CI 1.56–5.97, p = 0.001), hypernatremia (OR 3.49, 95% CI 1.32–9.23, p = 0.012), and hyponatremia (OR 4.24, 95% CI 1.52–11.85, p = 0.006) were independently associated with the development of moderate/severe AKI. Conclusions In pediatric patients after liver transplantation, PIM-3 score, and abnormal serum sodium levels were correlated with AKI development.
Read more »